ArticleThe Journal of antibiotics2022
A new metabolite, mannogeranylnerol, specifically produced at body temperature by Schizophyllum commune, a causative fungus of human mycosis.
Article in The Journal of antibiotics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Recurrent Pulmonary Infection Caused byRespirology case reports · 2025Article
- New Bioactive Sesquiterpeniods from the Plant-Derived Endophytic FungusJournal of fungi (Basel, Switzerland) · 2025Article
- Family matters inside the orderStudies in mycology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophyllum commune is a causative fungus of human mycosis. Its metabolites produced at 27 °C were compared with those produced at 37 °C, to obtain a candidate low-molecular-weight virulence factor related to the pathogenicity of this fungus. We found that S. commune specifically produces two acyclic terpene mannosides at 37 °C. They were identified as nerolidol β-D-mannoside (1) and geranylnerol β-D-mannoside (2) by NMR, MS, and CD analyses. Compound 2, a new compound named mannogeranylnerol, showed weak antibiotic activity that was slightly stronger than that of compound 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.